Skip to content
Top Alliance
Next generation biopharmaceuticals
Top Alliance
  • Home
  • Our Company
    • Our History
    • Our Leadership
    • Our Commitment
  • What We Do
    • Discovery
    • Research & Development
    • Manufacturing
  • Science
    • LOQTORZI™
    • Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Policy
  • Media
    • News Releases
    • Scientific Publications
    • Company Publications
  • Careers
  • Contact
  • Home
  • Our Company
    • Our History
    • Our Leadership
    • Our Commitment
  • What We Do
    • Discovery
    • Research & Development
    • Manufacturing
  • Science
    • LOQTORZI™
    • Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Policy
  • Media
    • News Releases
    • Scientific Publications
    • Company Publications
  • Careers
  • Contact

Recent news & events

Oct72020

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints

Press Release
Sep282020

JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma

Press Release
Sep102020

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab

Press Release
Aug92020

TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer

Press Release
Jul132020

Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement

Press Release
Jul122020

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016

Press Release
May262020

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

Press Release
May42020

Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

Press Release
Mar302020

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab

Press Release
Feb72020

IND for Junshi Biosciences’ FIH anti-BTLA antibody approved by FDA

Press Release
Load more
© TOPALLIANCE BIOSCIENCES - 2024. All rights reserved.

company.info@topalliancebio.com

Go to Top